BioLineRx (BLRX) Begins BL-8040 Phase 2 as Novel Stem Cell Mobilization Treatment – StreetInsider.com
|
BioLineRx (BLRX) Begins BL-8040 Phase 2 as Novel Stem Cell Mobilization Treatment
StreetInsider.com BioLineRx Ltd. (Nasdaq: BLRX) announced the initiation of a Phase 2 trial for BL-8040 as a novel approach for the mobilization and collection of bone marrow stem cells from the peripheral blood circulation. The Phase 2 open-label study will be … |
